CA
NZ
UK
AU
IND
US
Bristol-Myers Squibb (NYSE:BMY) sits at one of the most closely watched inflection points in large-cap pharma. The stock is in focus because the company is simultaneously managing the loss of exclusivity (LOE) on several legacy blockbusters, integrating a transformativeAcquisitionin neuroscience, executing a multibillion-dollar cost-savings …
Few names in large-cap pharmaceuticals draw as much attention right now as Merck & Co., Inc. (NYSE:MRK). The stock is in focus because the company just delivered a Q1 2026Earningsbeat, narrowed its full-year guidance higher, and continues to lay the groundwork for life after …
The Cigna Group (NYSE:CI) has spent the last twelve months reshaping itself, and investors are now watching to see whether that work translates into a sustained re-rating. After the closing of itsMedicareAdvantage divestiture to Health Care Service Corporation (HCSC) in March 2025, a "low-drama" …
The stock is in focus because Eli Lilly has emerged from 2025 with a degree of commercial momentum that few large-cap pharmaceutical companies have ever produced. Fourth-quarter 2025 results showedRevenueexpanding rapidly on the back of Mounjaro and Zepbound, while management's 2026 guidance came in …
Shares of Quantum BioPharma Ltd. (Nasdaq:QNTM) closed at $5.37 in the lastTrading session, advancing 20.67%, after its licensee Unbuzzd Wellness Inc. announced the appointment of Richard Buzbuzian as Chief Executive Officer. The move signals a structural shift from product development toward active commercial deployment, …
Clinical Trialsin rare oncology are rarely forgiving the second time. Soligenix (Nasdaq:SNGX) learned that on April 28, 2026, when its Data Monitoring Committee terminated the Phase 3 FLASH2 study of HyBryte for cutaneous T-cell lymphoma, recommending a halt for futility at the interim efficacy …
AxoGen (Nasdaq:AXGN) closed on April 28 up 6.60%, ending at USD 41.99, as first-quarter 2026 results cleared expectations on theRevenueline by a meaningfulMargin.Revenueof USD 61.5 million surpassed analyst forecasts of USD 57.85 million by 6.24%, driven by broad-basedDemandfor Avance Nerve Graft across the company's …
Glioblastoma remains among the most treatment-resistant cancers known to medicine. Median survival after diagnosis hovers around 15 months, and the therapeutic landscape has seen little meaningful innovation in over two decades. Against this backdrop, BioLineRx (Nasdaq:BLRX) and its partner Hemispherian AS announced on April …
In clinical-stage biotechnology, a single adverse event can reset years of accumulated investor confidence within hours. For Erasca (Nasdaq: ERAS), two successive sessions delivered compounding shocks: aPatentdispute on April 27 and a treatment-linked fatality disclosed on April 28, sending shares down 48.30% to close …
NeuroSense Therapeutics (Nasdaq:NRSN) surged 7.78% after announcing a USD 600,000 insider-led PIPE financing, with the CEO and CFO each committing USD 200,000 at a premium toMarket Priceahead of key clinical and regulatory milestones.Key HighlightsNeuroSense Therapeutics closed up 7.78% at USD 0.81 on April 28, …
Please wait processing your request...